SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

The Veil community is rallying around the project's focus on digital privacy and decentralization, often citing its multi-algorithm mining and staking capabilities as key differentiators. Investors are actively discussing the potential for a privacy-focused market surge, frequently highlighting the project's long-term utility alongside established privacy coins.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as heightened speculation around a potential buyout and unconfirmed M&A rumors drive significant after-hours volume and price volatility. Community members are actively debating the legitimacy of these reports, with long-term shareholders analyzing historical valuation metrics and potential takeover scenarios while others speculate on the motivations behind recent unusual trading patterns.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending due to significant liquidity concerns following the restricted withdrawal access in its private credit funds, which has sparked investor anxiety over potential sector-wide fallout. The community is actively debating whether this represents an isolated incident or a broader 'canary in the coal mine' moment for private credit stability amidst rising default risks.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

Investors are closely monitoring YETH as the community debates its weekly distribution payouts versus the underlying volatility of Ethereum. While some traders leverage the fund for its income potential during range-bound market phases, others remain cautious due to concerns regarding NAV erosion and management performance.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot is trending as investors rally around its narrative as an AI-generated project linked to the Grok wallet, fueling speculation about its potential for growth within the Base ecosystem. The community remains highly bullish, frequently discussing its low follower count as a sign of being early while emphasizing its unique connection to AI-driven token creation.

ARK ETF Trust - ARK Autonomous Technology & Robotics ETF

ARK Autonomous Technology & Robotics ETF

ARKQ is capturing investor attention as community members debate whether emerging robotics and 'embodied AI' infrastructure will take the tech sector's leadership baton this year. The ETF remains a focal point for discussion regarding portfolio rotation into automation themes, with sentiment driven by institutional buying activity and the sector's long-term growth potential.

Eaton Corp. Plc is a power management company, which provides energy-efficient solutions for electrical, hydraulic, and mechanical power. It operates through the following segments: Electrical Americas and Electrical Global; Aerospace, Vehicle, and eMobility. The Electrical Americas and Electrical Global segments engage in sales contracts for electrical components, industrial components, power distribution and assemblies, residential products, single and three phase power quality, wiring devices, circuit protection, utility power distribution, power reliability equipment, and service. The Aerospace segment supplies aerospace fuel, hydraulics, and pneumatic systems for commercial and military use. The Vehicle segment deals with the design, manufacture, marketing, and supply of drivetrain and powertrain systems and critical components that reduce emissions and improve fuel economy, stability, performance and safety of cars, light trucks and commercial vehicles. The eMobility segment designs, manufactures, markets, and supplies electrical and electronic components and systems that improve the power management and performance of both on-road and off-road vehicles. The company was founded in 1911 and is headquartered in Dublin, Ireland.

Eaton Corporation plc

Eaton Corporation is trending as a major beneficiary of the AI-driven data center expansion, with investors betting on its critical role in power infrastructure and cooling systems. The community is actively discussing its long-term growth as a core industrial leader while monitoring recent price action and technical setups following volatility in the sector.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Investors are closely watching the ARK Innovation ETF as it experiences sharp volatility, with community members expressing polarized views on Cathie Wood's aggressive buying and selling patterns amid broader market rotation out of high-beta growth stocks. The ongoing discourse highlights concerns over the fund's long-term performance and its heavy exposure to volatile tech and crypto-linked assets, leading to intense debates between those betting on an innovation-led rebound and those skeptical of the fund's strategy.

Monero

Monero (XMR) is trending as the community debates its role as the premier privacy-focused asset, with active discussions focusing on its unique resistance to regulatory oversight compared to transparent chains. Enthusiasts view it as a long-term store of value and a hedge against institutional tracking, while detractors continue to characterize the asset through speculative or cynical lenses.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

Investors are flocking to NEOS Nasdaq 100 High Income ETF (QQQI) to capture high monthly yields while maintaining core exposure to the Nasdaq 100. Community discussion centers on the fund's competitive edge over peers due to its tax-efficient return-of-capital structure and active management strategy, with many users dollar-cost averaging into positions as a long-term retirement income play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows.</li><li>Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.&nbsp;</li><li>Processa develops drugs for life-threatening and life-compromising chronic diseases.</li></ul>Shares of Processa Pharmaceuticals, Inc. (PCSA) closed up 6% and edged up 10% after hours on Thursday after several insiders at the company, including the CEO, made share purchases.According to filings made with the Securities and Exchange Commission, several insiders including Director Baluch Khoso, Chief Development Officer Bigora Sian, Chief Administrative Officer Guy Wendy, Chief Business Strategy Officer Lin Patrick, Chief Executive Officer Ng George K, Director Pannu Geraldine, Chief Financial Officer Skibsted Russell, President of Research &amp; Development Young David all bought shares of the company at a price of about $2.535 on the last day of March.CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows. Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.<h2 class="st-heading-2">About Processa</h2>Processa develops drugs for life-threatening and life-compromising chronic diseases. Its pipeline includes NGC-Cap and NGC-Iri for the treatment of certain cancers, PCS12852 for gastroparesis and constipation disorders and PCS499 for primary glomerular diseases. While the company has completed early-to-mid stage studies for PCS12852 and PCS499, mid-stage trials are in process for NGC-Cap. NGC-Iri, meanwhile, is still in preclinical stages.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PCSA stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.“Nice to see the little token insider purchases apparent "ploy" working just as designed. Predictable, like death and taxes,” a Stocktwits user wrote.<stembedurl>https://www.stocktwits.com/Jwa68/message/649316897</stembedurl>Another voiced optimism for the stock rallying up to $20.<stembedurl>https://www.stocktwits.com/Shallu/message/649328642</stembedurl><a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> has lost nearly 63% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lpcn-stock-crashes-heres-why/cZ7x6c9RI88">LPCN Stock Crashes 78%— Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PCSA Stock Rallies 10% After Hours— Here’s Why

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 

Equity

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 


<ul class="summary-bullets"><li>While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile, the company said.&nbsp;</li><li>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154.</li><li>The company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward.</li></ul>Shares of Lipocine Inc. (LPCN) fell 78% on Thursday after the company said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile enough to support outpatient administration without the need for healthcare provider monitoring, the company said. No treatment-related severe or serious adverse events were reported and no cases of excessive sedation or loss of consciousness were observed, it added.<h2 class="st-heading-2">What’s Next For Lipocine?</h2>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154. The company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with postpartum depression based on the post hoc analysis results, the company said.While it waits for the FDA to get back, the company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward, including continued development of LPCN 1154, development of other product candidates, strategic transactions, partnerships, and other opportunities, it said.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around LPCN rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user drew focus to the company’s remaining pipeline, which includes experimental drugs for the treatment of non-alcoholic steatohepatitis, for the management of symptoms associated with cirrhosis and another for the prevention of recurrent preterm birth.<stembedurl>https://www.stocktwits.com/Boknow/message/649308142</stembedurl>Another user expressed hopes for a minor recovery after the crash. &nbsp;<stembedurl>https://www.stocktwits.com/Ruttobillions/message/649292640</stembedurl><a href="https://stocktwits.com/symbol/LPCN">LPCN stock</a> has dropped 37% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sgml-stock-soars-on-100-m-bank-guarantee-retail-says-one-last-hurdle-is-behind/cZ7xCWQRI8Z">SGML Stock Soars On $100M Bank Guarantee, Retail Says 'One Last Hurdle' Is Behind</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Lipocine is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

LPCN Stock Crashes 78%— Here’s Why 

Lipocine said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.

<ul class="summary-bullets"><li>Cocrystal stated that the Fast Track designation is aimed at facilitating the development of drugs that treat serious conditions and address unmet medical needs, while also accelerating their review process by the FDA.</li><li>As a result of this designation, Cocrystal will be able to communicate more frequently and earlier with the FDA throughout the development of CDI-988.</li><li>The company stated that this will also allow for a rolling review of a New Drug Application.</li></ul>Cocrystal Pharma Inc. (COCP) stock soared more than 75% in Thursday’s pre-market trade after the company’s norovirus infection treatment received Fast Track designation from the U.S. Food and Drug Administration (FDA).Cocrystal stated that the Fast Track designation for CDI-988 allows for the treatment’s accelerated development and expedited regulatory review.<h2 class="st-heading-2">Why Is Fast Track Designation Important For CDI-988?</h2>Cocrystal stated that the Fast Track designation is aimed at facilitating the development of drugs that treat serious conditions and address unmet medical needs, while also accelerating their review process by the FDA.As a result of this designation, Cocrystal will be able to communicate early and more frequently with the FDA throughout the development of CDI-988. The company stated that this will also allow for a rolling review of a New Drug Application (NDA).CDI-988 may also qualify for Priority Review at the time of NDA submission.“We are pleased that the FDA has granted Fast Track designation for CDI-988, marking a significant milestone for Cocrystal and a critical step toward helping patients with norovirus,” said Cocrystal’s co-CEO, Sam Lee.Lee added that based on the data generated for CDI-988 so far, the company expects the treatment to potentially prevent as well as treat the norovirus infection.<h2 class="st-heading-2">Is Norovirus Infection A Serious Condition?</h2>Norovirus is a highly contagious virus that causes acute gastroenteritis. The infection can be serious due to rapid dehydration and is particularly dangerous for young children and the elderly.“While most people recover within a few days, immunocompromised individuals can experience chronic, long-term norovirus infections that can persist for weeks to years,” Lee added.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/COCP">Cocrystal Pharma</a> trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels.One bullish user on the platform termed the FDA Fast Track designation as a “big pharma type news for less than $5.”<stembedurl>https://stocktwits.com/cjstocksup/message/649279769</stembedurl><a href="https://stocktwits.com/symbol/COCP">COCP stock</a> is up 4% year-to-date, but down 28% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 17% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 20%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-china-made-ev-sales-march-2026/cZ7xoOYRI8R">Tesla’s China-Made EV Sales Rise 9% In March, Registering Fifth Straight Month Of Gains: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

COCP Stock Soars 75% — What Is The Link To Cocrystal’s Norovirus Treatment?

Cocrystal stated that the Fast Track designation for CDI-988 enables accelerated development and expedited regulatory review.

<ul class="summary-bullets"><li>PMGC Holdings (ELAB) is a holding company that acquires and runs businesses in manufacturing, biotech, and investments.</li><li>On Wednesday, the company announced&nbsp;the sale of $4.5 million of discounted stock to Streeterville Capital.</li><li>Stocktwits sentiment for ELAB remained ‘extremely bullish.’</li></ul>Shares of PMGC Holdings, Inc. (ELAB) staged a stunning run – soaring roughly 760% over the past three days – after one of its subsidiaries secured a long-term defense contract and the company’s annual report showed a 43% jump in assets.But the momentum appears to be faltering. ELAB shares&nbsp;crashed 52% overnight ahead of Thursday, following the company's announcement of a new share placement.<h2 class="st-heading-2">ELAB Dilution Concerns</h2>PMGC Holdings is raising another $4.55 million by issuing discounted stock to Streeterville Capital under an ongoing equity line, while registering those shares for resale, according to an exchange&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1840563/000121390026038645/0001213900-26-038645-index.htm">filing</a> late Wednesday.&nbsp;The move raised concerns about further dilution of the micro-cap stock. In September 2025, the company signed a $20 million equity line of credit facility (ELOC) and has tapped it multiple times since. With the latest placement, the credit line is fully utilized. “The proceeds are intended for general corporate purposes and potential acquisitions of operating companies,” the filing said.&nbsp;Streeterville is a Utah-based investment firm linked to John Fife, who in 2020 was charged by the Securities and Exchange Commission with operating as a “toxic lender” for years.&nbsp;Fife and his companies would purchase convertible notes from small, struggling companies, convert them into shares at substantial discounts, and sell the resulting stock without being registered as dealers — violating federal securities laws,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/enforcement-litigation/litigation-releases/lr-24886">according to the SEC</a>.<h2 class="st-heading-2">Retail’s View On ELAB</h2>On Stocktwits, traders appeared confused about the ELAB stock slide, given that the company was exercising a previously approved facility. Still, retail sentiment remained ‘extremely bullish,’ unchanged since the start of the week, although many expected significant volatility in the near term.$ELAB this is absolutely insane,”&nbsp;<a href="https://stocktwits.com/Costco_plays/message/649231502">remarked</a> a user. “A lot of panic sellers. But honestly, for me, my average was $7.X . Not that upset about this. It's setting up to be a very volatile stock that can squeeze heavy come tomorrow and Monday morning will be fun.”Another&nbsp;<a href="https://stocktwits.com/Costco_plays/message/649230144">wrote</a>: “Sooo like let me get this straight... It runs 133% (on Wednesday) and then drops 50%+ ? Do I smell manipulation? At these prices I'm sure people are going to buy this like crazy. Tomorrow we'll see a pop to $9 by morning bell.”<h2 class="st-heading-2">Recent Catalysts For ELAB</h2>PMGC Holdings is a diversified public holding company focused on acquiring and scaling cash-flowing businesses, primarily in U.S.-based manufacturing and industrial sectors, as well as in biotech and investment activities.&nbsp;Earlier this week, its engineering components unit AGA Precision Systems announced a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elab-stock-extends-rally-after-unit-signs-long-term-defense-deal/cZEPyYORIVl">long-term agreement</a> with Turbo-Jet Products Co. to supply mission-critical components for commercial and defense programs. Consequently, ELAB shares doubled on Monday.Last week, SVM Machining, another of PMGC’s units, secured ITAR registration from the U.S. Department of State, which allows it to work on controlled defense projects and positions it to enter U.S. military supply chains and regulated aerospace programs.&nbsp;Despite this week's rally,&nbsp;<a href="https://stocktwits.com/symbol/ELAB">ELAB shares</a> are still 60.6% lower year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ncno-stock-posts-best-day-in-7-months-after-strong-q4-analysts-still-see-over-50-upside/cZ7xQHeRIFN">NCNO Stock Posts Best Day In 7 Months After Strong Q4: Analysts Still See Over 50% Upside</a>

A trader checking stock market charts. ELAB shares dropped 52% overnight ahead of Thursday. (Picture source: Getty Images)

Why ELAB Stock Is Crashing Over 50% Overnight After 8x Surge This Week

Shares of PMGC Holdings, Inc. (ELAB) staged a stunning run – soaring roughly 760% over the past three days but ELAB shares crashed 52% overnight ahead of Thursday.

Retail investors on Stocktwits expect the stock to remain volatile.


<ul class="summary-bullets"><li>The deals, spread across more than 20 enterprise customers, are expected to generate approximately $7.5 million in revenue for the remainder of 2026.</li><li>The company currently has more than 30 active deployments spanning AI-native startups and established enterprises.</li></ul>&nbsp;Shares of Axe Compute Inc. (AGPU) closed 120% higher on Wednesday and edged up 19% after hours after the company said that it has signed deals worth about $12 million in total in the last 30 days, setting the stage for an estimated $835,000 in monthly recurring income as the company enters the second quarter.The deals, spread across more than 20 enterprise customers, are expected to generate approximately $7.5 million in revenue for the remainder of 2026 based on the current monthly run rate. The company currently has more than 30 active deployments spanning AI-native startups and established enterprises, with GPU hardware ranging from NVIDIA RTX 5090s to H100, H200 and B200 architectures.“This is not a marketing milestone — it is executed agreements from enterprises with production AI workloads,” said Chris Miglino, chief executive officer of Axe Compute. “Every agreement signed strengthens the foundation of the business. This is the beginning of our income from our GPU business and we are excited for this growth.”<h2 class="st-heading-2">About Axe Compute</h2>Axe Compute structures its enterprise contracts with monthly payments made in advance against reserved capacity, a model designed to minimize receivables risk and deliver predictable cash flow. The company says the payment terms reflect customer confidence in its ability to deliver reliable infrastructure quickly.The company positions itself as the enterprise GPU marketplace, giving AI innovators and enterprises access to any GPU architecture in any of 200+ global locations, deployed in as little as 24-48 hours. It was called Predictive Oncology until December and then renamed itself as part of its transformation to AI compute infrastructure. &nbsp;Earlier this week, the company reported full year total revenue of $125,284, derived entirely from the company’s drug discovery services legacy segment, and net loss from continuing operations of $232.9 million.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around AGPU stock rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed optimism over the pace at which the company landed GPU agreements.<stembedurl>https://www.stocktwits.com/Shake_Daddy/message/649223855</stembedurl>Another said that the pivot into AI compute is “working very well.”<stembedurl>https://www.stocktwits.com/Cpt_Sergio/message/649223370</stembedurl><a href="https://stocktwits.com/symbol/AGPU">AGPU stock</a> &nbsp;has lost 84% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-schizophrenia-study-fails/cZ7HygQRIFi">ANRO Stock On Investors’ Radar After Failed Schizophrenia Study Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did AGPU Stock Rise 120% Today?

The company signed deals worth $12 million, setting the stage for income from its new compute segment.

<ul class="summary-bullets"><li>Alto will now focus on its other programs including ALTO-207 in development for treatment -resistant depression.</li><li>The company said that it also intends to explore partnering opportunities for a modified-release oral formulation of ALTO-101 that it has developed.</li></ul>Shares of Alto Neuroscience, Inc. (ANRO) fell as much as 10% after hours on Wednesday after the company said that its experimental drug for the treatment of schizophrenia failed to achieve statistical significance on key goals in a mid-stage study.The company was studying ALTO-101 for the treatment of cognitive impairment associated with schizophrenia. However, no statistically significant changes were detected on primary electroencephalography or cognitive endpoints as compared to placebo, the company said.<h2 class="st-heading-2">Plans Ahead</h2>As a result, the company does not intend to independently advance ALTO-101 in CIAS anymore, it said, while adding that it would now focus on its other programs including ALTO-207 in development for treatment -resistant depression. Alto is looking to initiate a mid-stage trial for &nbsp;ALTO-207 in the first half of 2026. &nbsp;The company said that it now intends to explore partnering opportunities for a modified-release oral formulation of ALTO-101 that it has developed. The formulation has demonstrated an improved pharmacokinetic and tolerability profile when compared to the immediate-release formulation, Alto said, while adding that it believes the formulation may offer potential benefits across several therapeutic areas.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ANRO &nbsp;stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user noted the company’s balance sheet, terming it an “easy short.”<stembedurl>https://www.stocktwits.com/Shortski/message/649224122</stembedurl>The company said earlier this month that it had cash, cash equivalents, and restricted cash of approximately $177 million as of the end of 2025, expected to support its planned operations into 2028.Another user termed the selloff an “overreaction.”<stembedurl>https://www.stocktwits.com/RazorbackAJ/message/649224026</stembedurl> <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> has gained 32% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-agpu-stock-rise-today/cZ7HyVtRIF0">Why Did AGPU Stock Rise 120% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ANRO Stock Falls After Hours On Failed Schizophrenia Study Results

Alto Neuroscience does not intend to independently advance ALTO-101 in CIAS anymore, it said. 

<ul class="summary-bullets"><li>RenX stated that it completed its first deliveries in the premium compost market in 2025 and closed the year with $1.08 million in finished goods inventory.</li><li>The company also stated that it expects the Microtec UTM 1200 Turbo Mill precision milling system to arrive at the Myakka City facility in April 2026.</li><li>RenX added that it expects installation and commissioning to be completed within 2026, with commercial production targeted to begin in the second half of the year.</li></ul>RenX Enterprises Corp. (RENX) shares rallied more than 34% in Wednesday’s pre-market trade after the company beat its post-acquisition revenue guidance.RenX announced its fiscal year 2025 results, reporting $8.2 million in post-acquisition revenue following the June 2025 acquisition of RGUS. Its management guided for post-acquisition revenue of $7 million at the time.RenX said it retired $11.9 million in legacy debt, transitioning from a real estate holding company to a compost producer during the year.“The substrate industry is facing a supply chain problem that plays directly to our model. We enter 2026 with the platform in place and the market moving in our direction,” said RenX CEO David Villarreal.<h2 class="st-heading-2">First Deliveries In Compost Market</h2>RenX stated that it completed its first deliveries in the premium compost market in 2025 and closed the year with $1.08 million in finished goods inventory.The company also stated that it expects the Microtec UTM 1200 Turbo Mill precision milling system to arrive at the Myakka City facility in April 2026. RenX added that it expects installation and commissioning to be completed within 2026, with commercial production targeted to begin in the second half of the year.RenX stated that the Microtec precision milling system processes material already on-site and converts it into premium substrate products that command significantly higher per-ton prices than the current bulk compost output.Noting that the incremental economics of this system are “highly favorable,” RenX stated that it expects the system to drive consolidated gross margins toward 60% and above as it ramps, subject to production volume and market conditions.For fiscal 2025, RenX posted $15.9 million in loss and a blended gross margin of 29.1%.&nbsp;<h2 class="st-heading-2">RenX Completes Reverse Stock Split</h2>Last week, the company announced the completion of a 1-for-20 reverse stock split to regain compliance with Nasdaq’s minimum bid price requirements.Following this, the number of outstanding shares of the company’s common stock has been reduced to 2.5 million from 50 million, RenX said.In February 2026, RenX announced a private placement of $6 million primarily to meet its working capital requirements.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/RENX">RenX Enterprises</a> trended in the ‘neutral’ territory at the time of writing.One user highlighted that the RENX stock more than tripled in February, while noting that it remains to be seen if the company can maintain a higher market capitalization this time.<stembedurl>https://stocktwits.com/erb71/message/649153004</stembedurl>Another user stated that they are watching for a potential stock squeeze.<stembedurl>https://stocktwits.com/DPaul5151/message/649154121</stembedurl><a href="https://stocktwits.com/symbol/RENX">RENX stock</a> is down 53% year-to-date and 93% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 19% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nke-stock-tumbles-q4-outlook-china-weakness-nike-stock-downgrade-pt-cuts/cZ7HkFpRInM">Nike’s China Bet Is Under Pressure And Wall Street Is Losing Confidence – Analysts Warn Return To Growth Could Take 4 Quarters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock chart rising

RENX Stock Soars As RenX Enterprises Beats Post-Acquisition Revenue Guidance, Transitions From Real Estate To Compost Producer

RenX management guided for a post-acquisition revenue of $7 million, while the company reported $8.2 million in sales since closing the acquisition of RGUS through the end of 2025.

<ul class="summary-bullets"><li>New Era Energy added that the TCDC project is expected to be structured through a newly formed Delaware limited liability company.</li><li>The project’s financing will be led by an unnamed institutional investor, with debt accounting for about 80% of the funding, it said.</li><li>New Era Energy stated that its equity position in the venture is expected to generate distributions from operating cash flow after commercial operations of the first phase commence.</li></ul>New Era Energy &amp; Digital Inc. (NUAI) shares gained nearly 6% in Wednesday’s opening trade after the company announced a partnership for its flagship Texas data center facility.New Era Energy stated that it has entered into a non-binding letter of intent (LOI) to form a joint venture with Stream Data Centers for the development and financing of the company’s Texas Critical Data Centers (TCDC) facility in West Texas.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NUAI">New Era Energy</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Stream To Develop And Manage NUAI’s Facility</h2>New Era Energy stated that Stream will develop and manage the company’s data center facility, while leveraging the former’s local relationships.It added that the TCDC project is expected to be structured through a newly formed Delaware limited liability company. The project’s financing will be led by an unnamed institutional investor, with debt accounting for about 80% of the funding.The company added that its equity position in the venture is expected to generate distributions from operating cash flow after commercial operations of the first phase commence, providing a near-term path to recurring revenue.“This LOI represents an important step in advancing TCDC toward delivery, and we remain focused on progressing toward a definitive agreement with Stream,” said New Era Energy CEO E. Will Gray II.He added that the company expects to invest in the project alongside its partner amid a growing need for purpose-built, power-ready data center infrastructure.<h2 class="st-heading-2">TCDC Campus Spread Across 438 Acres</h2>New Era Energy’s TCDC campus is located in the Permian Basin of West Texas. The campus is spread across 438 acres owned by the company, with an additional 54-acre corridor that is currently pending approval.The TCDC campus is designed for a total capacity of over a gigawatt, with the expansion planned across three phases. The first phase will kick off with 200 megawatt capacity, while the second phase will add another 450 MW capacity. New Era Energy states that it will utilize utility-sourced power and on-site gas-fired energy in these two phases.The third phase is expected to take the total capacity to over a gigawatt. The company has projected that power delivery will be achieved by the end of 2027.In January 2026, New Era Energy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-nuai-stock-falling-today/cmyR4nVR4gX">announced</a> plans to raise up to $350 million to fund acquisitions, pay or refinance debt, meet capital expenditures, and other working capital requirements.<h2 class="st-heading-2">How Did Retail Traders React?</h2>One user stated that the partnership announced on Wednesday removes one of the biggest question marks for the company going forward.<stembedurl>https://stocktwits.com/roiger/message/649150963</stembedurl>Another user stated that this is big news for New Era Energy, adding that the company is “completely derisked now.”<stembedurl>https://stocktwits.com/YoloAlfred/message/649150643</stembedurl><a href="https://stocktwits.com/symbol/NUAI">NUAI stock</a> is up 39 % year-to-date and 256% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 17% over the past 12 months, while the Vanguard Extended Market Index Fund ETF (VXF) is up 20%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nke-stock-tumbles-q4-outlook-china-weakness-nike-stock-downgrade-pt-cuts/cZ7HkFpRInM">Nike’s China Bet Is Under Pressure And Wall Street Is Losing Confidence – Analysts Warn Return To Growth Could Take 4 Quarters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Computer racks in Data Center (Representative image courtesy of Arctic-Images via Getty Images)

Why Is NUAI Stock Rising Today? A Texas Data Center Deal Could Be Key

New Era Energy stated that it has entered into a non-binding letter of intent to form a joint venture with Stream Data Centers to develop and finance the facility.

<ul class="summary-bullets"><li>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction.</li><li>The company added that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029.</li><li>Korsana expects the financing round to close immediately prior to the proposed merger.</li></ul>Cyclerion Therapeutics Inc. (CYCN) shares more than tripled in Wednesday’s opening trade, rallying by more than 274% after the company announced a deal with Korsana Biosciences Inc.Cyclerion stated that it has entered into a definitive merger agreement for an all-stock transaction. The merged entity will operate under the name Korsana Biosciences Inc., and trade on the Nasdaq under the ticker symbol ‘KRSA’.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CYCN">Cyclerion Therapeutics</a> trended in the ‘neutral’ territory at the time of writing.<h2 class="st-heading-2">Korsana Secures $380M In Commitments To Support Merger</h2>Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction. The investment is led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, and Wellington Management, among others.The company expects the financing round to close immediately prior to the proposed merger.Korsana stated that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029, providing it with runway through key clinical milestones.“With our seasoned team and support from leading biotechnology investors, Korsana is well-positioned to advance a pipeline of innovative, next generation therapies,” said Korsana CEO Jonathan Violin.<h2 class="st-heading-2">What Does Korsana Do?</h2>Korsana is a Waltham, Massachusetts-based company that is engaged in the development of therapeutics to treat neurodegenerative diseases.Its lead program is KRSA-028, a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease, discovered in partnership with Paragon Therapeutics.KRSA-028 is designed to enhance amyloid plaque clearance, lower amyloid-related imaging abnormalities (ARIA) and hematologic risks, and improve convenience through low-volume subcutaneous delivery.<a href="https://stocktwits.com/symbol/CYCN">CYCN stock</a> is up 357% year-to-date and 128% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 19% over the past 12 months, while the Fidelity Nasdaq Composite Index ETF (ONEQ) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ipm-bcg-hubc-stocks-top-premarket-gainers-april-1-2026/cZ7H1jsRInn">IPM, BCG, HUBC Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

CYCN Stock Is Soaring 274% Today — What Is Fueling The Rally?

Cyclerion stated that it has entered into a definitive merger agreement with Korsana Therapeutics in an all-stock transaction.

<ul class="summary-bullets"><li>Earlier this month, Classover announced a reverse stock split in a bid to regain compliance with Nasdaq’s listing rules and meet the $1 minimum bid price requirement to ensure its securities remain listed on the stock exchange.</li><li>The company announced a 1-for-50 reverse stock split of its Class A common stock and Class B common stock, which went into effect on March 9, 2026.</li><li>Classover stated that it was notified by the Nasdaq that its stock had stayed above the $1 level for the previous 12 consecutive business days.</li></ul>Classover Holdings Inc. (KIDZ) shares soared nearly 61% in Tuesday’s pre-market trade after the company announced that it has regained compliance with the Nasdaq’s minimum bid price requirement.Classover stated that regaining compliance with Nasdaq’s listing rules will eliminate uncertainties regarding the trading of its securities.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/KIDZ">Classover Holdings</a> trended in the ‘neutral’ territory at the time of writing.<h2 class="st-heading-2">Classover Announced A Reverse Stock Split Earlier</h2>Earlier this month, Classover announced a reverse stock split in a bid to regain compliance with Nasdaq’s listing rules and achieve the $1 minimum bid price requirement to ensure its securities continued to be listed on the stock exchange.The company announced a 1-for-50 reverse stock split of its Class A common stock and Class B common stock, which went into effect on March 9, 2026.As a result of the reverse split, the number of outstanding shares of Class A common stock as of March 4, 2026 were reduced from 6.5 million to 130,700, and the number of outstanding shares of Class B common stock as of March 4, 2026, were reduced from 54.9 million to 1,097,731.<h2 class="st-heading-2">What Are Nasdaq’s Minimum Bid Price Requirements?</h2>The Nasdaq’s minimum bid price requirements for continued listing mandate that a company’s shares should be at or above $1 per share.If a stock falls below this level for 30 consecutive business days, the company is served a deficiency notice. Following this, the recipient is required to maintain a minimum bid price of $1 for at least 10 consecutive business days to regain compliance.Classover stated that it was notified by the Nasdaq that its stock had stayed above the $1 level for the previous 12 consecutive business days.<a href="https://stocktwits.com/symbol/KIDZ">KIDZ stock</a> is down 77% year-to-date and 99% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 15% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jeremy-siegel-us-stocks-fall-further-strait-hormuz-dow-fall-3800-points-iran-war/cZEPMsjRIVJ">Jeremy Siegel Warns US Stocks May Slide Further If Hormuz Crisis Drags On – Dow Is Already Down Nearly 3,800 Points Since Iran War Began</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

KIDZ Stock Rallies 61% Pre-Market Today — What Is Driving The Surge?

Classover stated that regaining compliance with Nasdaq’s listing rules will eliminate uncertainties with respect to the trading of its securities.

Vanguard Index Funds - Vanguard Extended Market Index ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

VXF
Vanguard Extended Market ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VXF News

VXFVanguard Extended Market ETF